Alcon (ALC) is well-poised to grow in the coming quarters, driven by its new product offerings. The performance of the Vision Care arm also appears encouraging. Strong financial stability in times of economic turmoil bodes well for the stock. However, concerns remain about the macroeconomic headwinds, which may strain the company’s margin performance. Competitive disadvantages also add to the worry.In the past year, this Zacks Rank #2 (Buy) stock has advanced 14.6% compared with the 12.1% rise of the indust ...

Investors interested in Medical stocks should always be looking to find the best-performing companies in the group. Alcon (ALC) is a stock that can certainly grab the attention of many investors, but do its recent returns compare favorably to the sector as a whole? Let's take a closer look at the stock's year-to-date performance to find out.Alcon is a member of our Medical group, which includes 1047 different companies and currently sits at #7 in the Zacks Sector Rank. The Zacks Sector Rank considers 16 dif ...

The Medical Instruments industry has been witnessing a gradual transition from remote healthcare and contactless services during the pandemic to its original space of point-of-care testing, heavy as well as minimally invasive implants, elective procedures, and so on. This industry is highly fragmented, with participants engaged in research and development (R&D) in therapeutic areas.The Zacks defined Medical Instruments industry has advanced 8.9% in the past year and 9.7% year to date, respectively. Since th ...

Market watchers had a bearish view for MedTech stocks ahead of the first-quarter earnings season, thanks to the ongoing geopolitical discord across the globe with major complications arising from the Middle-East conflicts. Security threats around the Red Sea were alarming through the months of the first quarter, leading to a significant rise in freight costs and shipping times. Added to this, healthcare labor shortages continued to act as a major business disruptor.While these remarkably reduced the gross a ...

Alcon, Inc. (ALC) delivered core earnings per share (EPS) of 78 cents in the first quarter of 2024, up 11% from the year-ago quarter’s figure (up 21% at the constant exchange rate or CER). The figure topped the Zacks Consensus Estimate by 8.3%. Alcon’s ‘core’ results are based on non-IFRS (International Financial Reporting Standards) measures.In the first quarter, the company’s diluted EPS was 50 cents, up 43% year over year.Revenues in DetailAlcon’s net sales to third parties in the first quarter were $2.4 ...

Alcon Inc. (NYSE:ALC) Q1 2024 Earnings Conference Call May 14, 2024 8:00 AM ET Company Participants Dan Cravens - Vice President, Investor Relations David Endicott - Chief Executive Officer Tim Stonesifer - Chief Financial Officer Conference Call Participants Graham Doyle - UBS Veronica Dubajova - Citi Ryan Zimmerman - BTIG Richard Felton - Goldman Sachs Larry Biegelsen - Wells Fargo Jack Reynolds-Clark - RBC Capital Markets David Saxon - Needham & Co Michael Sarcone - Jefferies Brett Fishbin - KeyBanc Capi ...

Alcon (ALC) reported $2.44 billion in revenue for the quarter ended March 2024, representing a year-over-year increase of 4.8%. EPS of $0.78 for the same period compares to $0.70 a year ago.The reported revenue represents a surprise of -0.64% over the Zacks Consensus Estimate of $2.46 billion. With the consensus EPS estimate being $0.72, the EPS surprise was +8.33%.While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how they compare to Wall Street expectat ...

Among the medical sector, Alcon (ALC)  and Prestige Consumer Healthcare (PBH)  are two intriguing stocks to buy for growth as their quarterly results approach on Tuesday, May 14.Alcon stands out as a provider of a full suite of eye care products while Prestige distributes over-the-counter (OTC) healthcare and household cleaning products. Let’s take a look at their expansion and get a better gauge as to why now is a good time to buy Alcon and Prestige’s stock.Alcon Preview Alcon primarily provides ophthalmic ...

Earnings Estimate Revisions - Alcon Inc (ALC) is seeing favorable earnings estimate revisions, which is a precursor to a potential earnings beat [1] - The Most Accurate Estimate for the current quarter is 74 cents per share, compared to the Zacks Consensus Estimate of 72 cents per share [1] - This results in a Zacks Earnings ESP of +2.57% for ALC heading into earnings season [1] Importance of Positive Earnings ESP - A positive Zacks Earnings ESP has historically been powerful in producing positive surprises and outperforming the market [2] - Stocks with a positive Earnings ESP and a Zacks Rank 3 (Hold) or better show a positive surprise nearly 70% of the time [2] - These stocks have returned over 28% on average in annual returns [2] Alcon's Position - ALC has a Zacks Rank 2 (Buy) and a positive Earnings ESP, making it a potential candidate for consideration ahead of earnings [2] - Recent earnings estimate revisions suggest positive prospects for Alcon and a potential earnings beat in the upcoming report [2]

Investors interested in stocks from the Medical - Instruments sector have probably already heard of Alcon (ALC) and Edwards Lifesciences (EW) . But which of these two stocks presents investors with the better value opportunity right now? Let's take a closer look.The best way to find great value stocks is to pair a strong Zacks Rank with an impressive grade in the Value category of our Style Scores system. The Zacks Rank favors stocks with strong earnings estimate revision trends, and our Style Scores highli ...